Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG -3.92%58 EV-to-EBITDA is 62.67 as of Aug. 06, 2026. GuruFocus rates TXG with a GF Score™ of 58/100 and a GF Value™ of $18.84 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 510 Healthcare Providers & Services companies, 10x Genomics ranks worse than 93.53% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, 10x Genomics's enterprise value is $5,330.7 Mil.
10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $85.1 Mil. Therefore, 10x Genomics's EV-to-EBITDA for today is 62.67.
The historical rank and industry rank for 10x Genomics's EV-to-EBITDA or its related term are showing as below:
TXG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -657.25 Med: -33.56 Max: 66.19
Current: 62.67
During the past 9 years, the highest EV-to-EBITDA of 10x Genomics was 66.19. The lowest was -657.25. And the median was -33.56.
TXG's EV-to-EBITDA is ranked worse than 93.53% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 11.07
vs TXG: 62.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
10x Genomics's PE Ratio (TTM) for today is calculated as:
10x Genomics's share price for today is $45.60.
10x Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for 10x Genomics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where 10x Genomics's EV-to-EBITDA falls into.
10x Genomics's current Enterprise Value is $5,330.7 Mil.
10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $85.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a EV-to-EBITDA of 62.67 as of Aug. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on 10x Genomics. According to the industry distribution chart, 10x Genomics ranks #477 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 93.5%.
Is 10x Genomics' EV-to-EBITDA too high?
10x Genomics' current EV-to-EBITDA is 62.67. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.07. 10x Genomics' value of 62.67 is 466.1% above this industry median. Based on the distribution chart, 10x Genomics ranks #477 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, 10x Genomics has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' EV-to-EBITDA compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #477 out of 510 companies for EV-to-EBITDA. This places 10x Genomics in the lower half of its industry. The industry median EV-to-EBITDA is 11.07. 10x Genomics' value of 62.67 is 466.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.07, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current EV-to-EBITDA of 62.67 is 466.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on 10x Genomics. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current EV-to-EBITDA is 62.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.84, compared to a current price of $45.60 — trading 142% above its estimated fair value. The current EV-to-EBITDA is 62.67 and 466.1% above the Healthcare Providers & Services industry median of 11.07. 10x Genomics' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For 10x Genomics (TXG), the current EV-to-EBITDA is 62.67 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $45.60 is trading 142% above its estimated GF Value™ of $18.84.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
EV-to-EBITDA: 62.67
GF Value™: $18.84 vs. price of $45.60 (142% above fair value)
Industry Position: 466.1% above the Healthcare Providers & Services median (#477 of 510)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
58GF Score
Get the complete analysis for TXG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
